SCHEDULE 13G/A 0001628280-23-005045 0001757283 XXXXXXXX LIVE 1 Common Stock, $0.0001 par value per share 06/30/2025 0001933414 MINERALYS THERAPEUTICS, INC. 603170101 150 N. Radnor Chester Road, Suite F200 Radnor PA 19087 Rule 13d-1(c) Andera Partners I0 0.00 2765976.00 0.00 2765976.00 2765976.00 4.2 OO BioDiscovery 6 FPCI I0 0.00 2765976.00 0.00 2765976.00 2765976.00 4.2 OO Stephane Bergez I0 0.00 2765976.00 0.00 2765976.00 2765976.00 4.2 IN Francois Xavier Mauron I0 0.00 2765976.00 0.00 2765976.00 2765976.00 4.2 IN MINERALYS THERAPEUTICS, INC. 150 N. Radnor Chester Road, Suite F200, Radnor, PA, 19087. The names of the persons filing this report (collectively, the "Reporting Persons") are: BioDiscovery 6 FPCI ("BioDiscovery 6") Andera Partners ("Andera") Stephane Bergez ("Bergez") Francois Xavier Mauron ("Mauron") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G. 2 place de Rio de Janeiro 75008 Paris France BioDiscovery 6 France Andera France Bergez France Mauron France Y Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. BioDiscovery 6 is the record holder of 2,765,976 shares of common stock. Voting and dispositive decisions with respect to the securities held by BioDiscovery 6 are made by its management company, Andera. The managing partners of Andera are Bergez and Mauron. As a result, each of the Reporting Persons may be deemed to beneficially own the securities held by BioDiscovery 6. Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. The percentage set forth in each row 11 is based upon 65,175,287 shares of common stock outstanding as of May 8, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on May 12, 2025. Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1 Joint Filing Agreement Andera Partners /s/ Stephane Bergez 08/14/2025 BioDiscovery 6 FPCI /s/ Stephane Bergez 08/14/2025 Stephane Bergez /s/ Stephane Bergez 08/14/2025 Francois Xavier Mauron /s/ Francois Xavier Mauron 08/14/2025